Fibroblast growth factor receptor-immunoglobulin fusion
AssigneeChiron Corporation
InventorsW. Michael Kavanaugh, Marcus Ballinger
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for inhibiting cell proliferation, especially angiogenesis. The invention specifically relates to fusions of the extracellular domain of a fibroblast growth factor receptor (FGFR) with a heterologous oligomerization domain, such as that contained in an immunoglobulin, to provide potent FGFR antagonists.
Claims13
A fusion polypeptide comprising a fibroblast growth factor (FGF) receptor extracellular domain fused to a heterologous oligomerization domain wherein said extracellular domain comprises the acid box and lacks the Ig I segment, and wherein said heterologous oligomerization domain is the Fe region of an immunoglobulin class G molecule, wherein said FGF receptor is human FGFR1.
A fusion polypeptide having the amino acid sequence selected from the group consisting of:
- a) the amino acid sequence set forth in SEQ ID NO:2;
- b) an amino acid sequence having at least 75% identity to the amino acid sequence set forth in SEQ ID NO:2;
- and
- c) an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:2,
- wherein said polypeptide comprises the acid box set forth as amino acid residues 126-133 of SEQ ID NO:2 and is capable of binding FGF.
A polynucleotide construct having the sequence selected from the group consisting of:
- a) the nucleotide sequence set forth in SEQ ID NO:1;
- b) a nucleotide sequence having at least 75% identity to the nucleotide sequence set forth in SEQ ID NO:1;
- and
- c) a nucleolide sequence having at least 95% identity to the nucleotide sequence set forth in SEQ ID NO:1,
- wherein said polylnucleotidc construct encodes a fusion polypeptide that comprises the acid box set forth as amino acid residues 126-133 of SEQ ID NO:2 and is capable of binding FGF.
Dependencies are inferred from the claim text.